- Home
- IGA vs KZIA Comparison
IGA vs KZIA Comparison
Compare IGA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGA | KZIA |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 161.5M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | IGA | KZIA |
|---|---|---|
| Price | $9.77 | $9.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 42.3K | ★ 2.0M |
| Earning Date | 01-01-0001 | 12-26-2025 |
| Dividend Yield | ★ 8.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,199,108.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.77 | $2.86 |
| 52 Week High | $8.88 | $21.00 |
Technical Indicators
Market Signals| Indicator | IGA | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 47.01 |
| Support Level | $9.72 | $11.75 |
| Resistance Level | $9.79 | $17.40 |
| Average True Range (ATR) | 0.08 | 2.77 |
| MACD | 0.02 | -0.21 |
| Stochastic Oscillator | 60.00 | 21.35 |
Price Performance
Historical ComparisonAbout IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.